Table 1.
Demographic and Clinical Characteristics of Participants
| Characteristic | Discovery Set |
Replication Sets* |
||||||
|---|---|---|---|---|---|---|---|---|
| UK Biobank |
PLCO |
ILCCO-OncoArray |
TRICL |
|||||
| Incident LC | Non-LC | Incident LC | Non-LC | LC Cases | Controls | LC Cases | Controls | |
| Sample size† | 4,083 | 334,643 | 2,455 | 96,196 | 15,827 | 12,783 | 4,886 | 5,259 |
| Age, yr,‡ mean ± SD | 61.65 ± 5.89 | 55.89 ± 8.07 | 63.92 ± 5.01 | 62.27 ± 5.28 | 63.45 ± 10.56 | 62.15 ± 10.92 | 60.78 ± 10.08 | 58.39 ± 9.39 |
| Sex, male | 2,093 (51.3) | 152,165 (45.5) | 1,493 (60.8) | 46,140 (48.0) | 9,836 (62.1) | 7,671 (60.0) | 2,657 (54.4) | 2,816 (53.5) |
| Smoking status | ||||||||
| Never | 649 (15.9) | 184,204 (55) | 225 (9.2) | 47,041 (48.9) | 1,497 (9.5) | 4,186 (32.7) | 500 (10.2) | 1,656 (31.5) |
| Current | 1,824 (44.7) | 115,030 (34.4) | 944 (38.5) | 7,822 (8.1) | 5,473 (34.6) | 4,249 (33.2) | 1,719 (35.2) | 1,807 (34.4) |
| Former | 1,577 (38.6) | 34,318 (10.3) | 1,286 (52.4) | 41,319 (43) | 8,499 (53.7) | 4,035 (31.6) | 2,667 (54.6) | 1,796 (34.2) |
| Unknown | 33 (0.8) | 1,091 (0.3) | 0 | 14 (0.0) | 358 (2.3) | 313 (2.4) | 0 | 0 |
| Histology | ||||||||
| LUAD | 1,359 (33.3) | — | 776 (31.6) | — | 6,622 (41.8) | — | 1,786 (36.6) | — |
| LUSC | 694 (17) | — | 371 (15.1) | — | 3,944 (24.9) | — | 955 (19.5) | — |
| SCC | 282 (6.9) | — | 252 (10.3) | — | 1,616 (10.2) | — | 463 (9.5) | — |
| Other | 451 (11.0) | — | 431 (17.6) | — | 3,645 (23.1) | — | 1,682 (34.4) | — |
| Unknown | 1,297 (31.8) | — | 625 (25.4) | — | 0 | — | 0 | — |
Definition of abbreviations: ILCCO-OncoArray = International Lung Cancer OncoArray Consortium; LC = lung cancer; LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma; PLCO = Prostate, Lung, Colorectal, and Ovarian cancer screening trial; SCC = small-cell lung cancer; TRICL = Transdisciplinary Research in Cancer of the Lung.
Data are presented as n (%) unless otherwise noted.
In FinnGen, 3,061 incident lung cancer cases and 204,021 cancer-free controls were included in the analysis. Lung cancer included 929 (30.3%) LUADs, 696 (22.7%) LUSCs, and 346 (11.3%) SCCs. Detailed baseline characteristics of age, sex, and smoking status in FinnGen have not been released.
All the participants are of European ancestry.
Age of lung cancer cases is the age at cancer diagnosis (ILCCO-OncoArray and TRICL) or age at enrollment (UK Biobank and PLCO trial), whereas the age of controls is the age at participant enrollment and blood collection.